Skip to main content

Table 4 Analysis using a mixed effects model for AEs and risk factors associated with the EQ-5D-5L utility value in patients who received chemotherapy

From: Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study

Factors Coefficient 95% CI P value
Nausea −0.015 −0.046 – 0.015 0.339
Anorexia −0.043 −0.067 – − 0.019 0.001
Pain −0.051 − 0.083 – − 0.019 0.002
Fatigue − 0.001 − 0.025 – 0.024 0.966
Peripheral neuropathy −0.021 − 0.041 – 0.002 0.035
Dysgeusia 0.015 −0.007 – 0.038 0.197
Female −0.022 −0.092 – 0.047 0.543
Age (IQR:61.5–75) −0.016 −0.065 – 0.032 0.524
mGPS (IQR:0–2) −0.003 −0.034 – 0.028 0.870
Distant metastasis −0.013 −0.067 – 0.039 0.626
FOLFIRINOX 0.021 −0.026 – 0.068 0.400
NLR (IQR:1.4–3.1) 0.002 −0.005 – 0.009 0.603
CEA, μg/L (IQR:2.8–8.3) −0.001 −0.002 – 0 0.125
Time from start of first-line chemotherapy, day (IQR:112–386) −0.007 −0.023 – 0.008 0.365
  1. mGPS modified Glasgow prognostic score, NLR Neutrophil-lymphocyte ratio, CEA Carcinoembryonic antigen, IQR Inter-quartile range (25–75th percentiles)
  2. Coefficient for continuous variables indicate the difference of mean in QOL for the increment in IQR